Conavi

About Conavi

Conavi Medical operates as a commercial-stage medical device company, directing its focus on the development and commercialization of image guidance technologies for minimally invasive cardiovascular procedures. The company was co-founded in 2007 by Dr. Brian Courtney and Aman Thind, PhD. Dr. Courtney, who also serves as the company's Chief Medical Officer, is an interventional cardiologist with a background in computer engineering from the University of Waterloo and Stanford University. This blend of clinical practice and engineering expertise was foundational to the company's inception, aiming to address unmet clinical needs identified during patient care.

The company's business model centers on the design, manufacturing, and sale of its proprietary imaging systems to hospitals and medical facilities. Its primary clients are interventional cardiologists who perform procedures like angioplasty and stenting. Conavi's main product is the Novasight Hybrid System, which is the first and only commercially available platform that simultaneously combines two critical intravascular imaging modalities: intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device. This addresses a significant limitation in the field, where physicians previously had to choose between the deeper tissue penetration of IVUS or the high-resolution imaging of OCT. The Novasight system provides co-registered images, offering a comprehensive view of coronary arteries to assess plaque, guide stent placement, and ultimately improve patient outcomes. The system consists of a console and single-use catheters, which allows hospitals to save space and reduce costs by maintaining one system instead of two separate ones.

Conavi has achieved significant regulatory milestones, securing 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Novasight Hybrid System in April 2018. It also has regulatory approvals in Canada, Japan, and China. The company has a second product, the Foresight Intracardiac Echocardiography (ICE) system, which provides 2D and 3D ultrasound imaging of the heart's chambers and has also received FDA and Health Canada approval. To fund its development and commercialization efforts, Conavi has raised significant capital, including a $20 million public offering in April 2025. The company is publicly traded on the TSX Venture Exchange.